Lupin Subsidiary Settles Antitrust Lawsuit for USD 30 Mn

Lupin's wholly-owned US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has settled a civil lawsuit related to alleged anticompetitive behavior. The lawsuit, part of the "In Re Generic Pharmaceuticals Antitrust Litigation," involved multiple claims against LPI. To avoid further litigation costs and uncertainties, LPI entered a settlement agreement with Humana Inc., one of the plaintiffs. Under the agreement, LPI will pay USD 30 million for a full release of all claims. Lupin stated that this settlement amount was already provisioned in its prior consolidated financial results. LPI explicitly denies all allegations and any admission of liability or unlawful conduct.